Targeting SHP-1-Mediated Inhibition of STAT3 and ERK Signalling Pathways Rescues the Hyporesponsiveness of MHC-I-Deficient NK-92MI

Abstract

Natural Killer (NK) cells have shown promising prospects in ‘off-the-shelf’ cell therapy, particularly the NK-92 cell line, which can serve as a foundation for the next generation of universal chimeric antigen receptor (CAR)-engineered NK products. A key strategy for generating universal cellular products is the elimination of the beta-2-microglobulin (B2M) gene, which encodes a component of MHC class I molecules (MHC-I) that plays a role in the presentation of foreign antigens and in the ‘licensing’ or ‘education’ of NK cells. To functionally study the impacts of MHC-I deficiency on NK-92, we generated a B2M knockout (KO) NK-92MI (B-92) cell line and compared the multidimensional properties of B2M KO and wild-type NK-92MI cells in terms of biological phenotypes, effector functions, and transcriptomic signatures. We observed a decrease in activating receptors, cytokine production, and cytotoxicity in B-92 cells. Further analysis of signalling events revealed that the upregulated expression and phosphorylation of SHP-1 in B-92 cells inhibited the phosphorylation levels of STAT3 and ERK, thereby affecting their killing function. By knocking out SHP-1 (PTPN6), we partially restored the cytotoxic function of B-92 cells. Notably, we also found that CAR modification can overcome the hyporesponsiveness of B-92 cells. These findings will facilitate further exploration in the development of NK cell-based products.

Keywords

ERK1/2 / MHC-I / NK cells / SHP-1 / STAT3

References

[1] F. Fang, S. Xie, M. Chen, et al., “Advances in NK Cell Production,” Cellular and Molecular Immunology 19, no. 4 (2022): 460-481.

[2] O. Dufva, S. Gandolfi, J. Huuhtanen, et al., “Single-Cell Functional Genomics Reveals Determinants of Sensitivity and Resistance to Natural Killer Cells in Blood Cancers,” Immunity 56, no. 12 (2023): 2816-2835.

[3] S. Cooley, F. Xiao, M. Pitt, et al., “A Subpopulation of Human Peripheral Blood NK Cells That Lacks Inhibitory Receptors for Self-MHC Is Developmentally Immature,” Blood 110, no. 2 (2007): 578-586.

[4] T. Tonn, S. Becker, R. Esser, D. Schwabe, and E. Seifried, “Cellular Immunotherapy of Malignancies Using the Clonal Natural Killer Cell Line NK-92,” Journal of Hematotherapy and Stem Cell Research 10, no. 4 (2001): 535-544.

[5] H. Klingemann, L. Boissel, and F. Toneguzzo, “Natural Killer Cells for Immunotherapy—Advantages of the NK-92 Cell Line Over Blood NK Cells,” Frontiers in Immunology 7 (2016): 91.

[6] T. Tonn, D. Schwabe, H. G. Klingemann, et al., “Treatment of Patients With Advanced Cancer With the Natural Killer Cell Line NK-92,” Cytotherapy 15, no. 12 (2013): 1563-1570.

[7] R. C. Sterner and R. M. Sterner, “CAR-T Cell Therapy: Current Limitations and Potential Strategies,” Blood Cancer Journal 11, no. 4 (2021): 69.

[8] J. H. Gong, G. Maki, and H. G. Klingemann, “Characterization of a Human Cell Line (NK-92) With Phenotypical and Functional Characteristics of Activated Natural Killer Cells,” Leukemia 8, no. 4 (1994): 652-658.

[9] Y. K. Tam, J. A. Martinson, K. Doligosa, and H. G. Klingemann, “Ex Vivo Expansion of the Highly Cytotoxic Human Natural Killer-92 Cell-Line Under Current Good Manufacturing Practice Conditions for Clinical Adoptive Cellular Immunotherapy,” Cytotherapy 5, no. 3 (2003): 259-272.

[10] P. Zuo, Y. Li, C. He, et al., “Anti-Tumor Efficacy of Anti-GD2 CAR NK-92 Cells in Diffuse Intrinsic Pontine Gliomas,” Frontiers in Immunology 14 (2023): 1145706.

[11] F. Wang, L. Wu, L. Yin, H. Shi, Y. Gu, and N. Xing, “Combined Treatment With Anti-PSMA CAR NK-92 Cell and Anti-PD-L1 Monoclonal Antibody Enhances the Antitumour Efficacy Against Castration-Resistant Prostate Cancer,” Clinical and Translational Medicine 12, no. 6 (2022): e901.

[12] L. Zheng, H. Wang, J. Zhou, et al., “Off-The-Shelf CAR-NK Cells Targeting Immunogenic Cell Death Marker ERp57 Execute Robust Antitumor Activity and Have a Synergistic Effect With ICD Inducer Oxaliplatin,” Journal for Immunotherapy of Cancer 12, no. 7 (2024): e008888.

[13] X. Lin, Z. Liu, X. Dong, et al., “Radiotherapy Enhances the Anti-Tumor Effect of CAR-NK Cells for Hepatocellular Carcinoma,” Journal of Translational Medicine 22, no. 1 (2024): 929.

[14] M. G. Netea, J. Quintin, and J. W. van der Meer, “Trained Immunity: A Memory for Innate Host Defense,” Cell Host and Microbe 9, no. 5 (2011): 355-361.

[15] L. Ruggeri, M. Capanni, E. Urbani, et al., “Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants,” Science 295, no. 5562 (2002): 2097-2100.

[16] D. Y. Torrejon, M. Galvez, G. Abril-Rodriguez, et al., “Antitumor Immune Responses in B2M-Deficient Cancers,” Cancer Immunology Research 11, no. 12 (2023): 1642-1655.

[17] Y. Guo, B. Xu, Z. Wu, et al., “Mutant B2M-HLA-E and B2M-HLA-G Fusion Proteins Protects Universal Chimeric Antigen Receptor-Modified T Cells From Allogeneic NK Cell-Mediated Lysis,” European Journal of Immunology 51, no. 10 (2021): 2513-2521.

[18] L. H. Gaykema, R. Y. van Nieuwland, E. Lievers, et al., “T-Cell Mediated Immune Rejection of Beta-2-Microglobulin Knockout Induced Pluripotent Stem Cell-Derived Kidney Organoids,” Stem Cells Translational Medicine 13, no. 1 (2024): 69-82.

[19] P. Lu, J. Chen, L. He, et al., “Generating Hypoimmunogenic Human Embryonic Stem Cells by the Disruption of Beta 2-Microglobulin,” Stem Cell Reviews and Reports 9, no. 6 (2013): 806-813.

[20] L. Riolobos, R. K. Hirata, C. J. Turtle, et al., “HLA Engineering of Human Pluripotent Stem Cells,” Molecular Therapy 21, no. 6 (2013): 1232-1241.

[21] D. Wang, Y. Quan, Q. Yan, J. E. Morales, and R. A. Wetsel, “Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells,” Stem Cells Translational Medicine 4, no. 10 (2015): 1234-1245.

[22] Y. Zhang, Y. Wang, L. Shao, et al., “Knockout of Beta-2 Microglobulin Reduces Stem Cell-Induced Immune Rejection and Enhances Ischaemic Hindlimb Repair via Exosome/miR-24/Bim Pathway,” Journal of Cellular and Molecular Medicine 24, no. 1 (2020): 695-710.

[23] L. Schmied, T. T. Luu, J. N. Søndergaard, et al., “SHP-1 Localization to the Activating Immune Synapse Promotes NK Cell Tolerance in MHC Class I Deficiency,” Science Signaling 16, no. 780 (2023): eabq0752.

[24] N. A. Cacalano, “Regulation of Natural Killer Cell Function by STAT3,” Frontiers in Immunology 7 (2016): 128.

[25] K. Jiang, B. Zhong, D. L. Gilvary, et al., “Pivotal Role of Phosphoinositide-3 Kinase in Regulation of Cytotoxicity in Natural Killer Cells,” Nature Immunology 1, no. 5 (2000): 419-425.

[26] F. Komatsu and M. Kajiwara, “Relation of Natural Killer Cell Line NK-92-Mediated Cytolysis (NK-92-Lysis) With the Surface Markers of Major Histocompatibility Complex Class I Antigens, Adhesion Molecules, and Fas of Target Cells,” Oncology Research 10, no. 10 (1998): 483-489.

[27] E. Masle-Farquhar, K. J. Jackson, T. J. Peters, et al., “STAT3 Gain-Of-Function Mutations Connect Leukemia With Autoimmune Disease by Pathological NKG2D(Hi) CD8(+) T Cell Dysregulation and Accumulation,” Immunity 55, no. 12 (2022): 2386-2404.

[28] S. Zhu, P. V. Phatarpekar, C. J. Denman, et al., “Transcription of the Activating Receptor NKG2D in Natural Killer Cells Is Regulated by STAT3 Tyrosine Phosphorylation,” Blood 124, no. 3 (2014): 403-411.

[29] Y. Kagoya, S. Tanaka, T. Guo, et al., “A Novel Chimeric Antigen Receptor Containing a JAK-STAT Signaling Domain Mediates Superior Antitumor Effects,” Nature Medicine 24, no. 3 (2018): 352-359.

[30] W. Glienke, R. Esser, C. Priesner, et al., “Advantages and Applications of CAR-Expressing Natural Killer Cells,” Frontiers in Pharmacology 6 (2015): 21.

[31] H. G. Klingemann, “Cellular Therapy of Cancer With Natural Killer Cells-Where Do We Stand?,” Cytotherapy 15, no. 10 (2013): 1185-1194.

[32] E. Ingulli, “Mechanism of Cellular Rejection in Transplantation,” Pediatric Nephrology 25, no. 1 (2010): 61-74.

[33] N. L. de Vries, J. van de Haar, V. Veninga, et al., “γδ T Cells Are Effectors of Immunotherapy in Cancers With HLA Class I Defects,” Nature 613, no. 7945 (2023): 743-750.

[34] H. Xu, B. Wang, M. Ono, et al., “Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs With Enhanced Immune Compatibility,” Cell Stem Cell 24, no. 4 (2019): 566-578.e7.

[35] S. Y. Neo, L. Tong, J. Chong, et al., “Tumor-Associated NK Cells Drive MDSC-Mediated Tumor Immune Tolerance Through the IL-6/STAT3 Axis,” Science Translational Medicine 16, no. 747 (2024): eadi2952.

[36] Y. Chen, Y. Zhou, Z. Zhou, et al., “Hypoimmunogenic Human Pluripotent Stem Cells Are Valid Cell Sources for Cell Therapeutics With Normal Self-Renewal and Multilineage Differentiation Capacity,” Stem Cell Research and Therapy 14, no. 1 (2023): 11.

[37] Y. Kagoya, T. Guo, B. Yeung, et al., “Genetic Ablation of HLA Class I, Class II, and the T-Cell Receptor Enables Allogeneic T Cells to be Used for Adoptive T-Cell Therapy,” Cancer Immunology Research 8, no. 7 (2020): 926-936.

[38] K. Hoerster, M. Uhrberg, C. Wiek, et al., “HLA Class I Knockout Converts Allogeneic Primary NK Cells Into Suitable Effectors for “Off-The-Shelf” Immunotherapy,” Frontiers in Immunology 11 (2020): 586168.

[39] M. D. Bern, B. A. Parikh, L. Yang, D. L. Beckman, J. Poursine-Laurent, and W. M. Yokoyama, “Inducible Down-Regulation of MHC Class I Results in Natural Killer Cell Tolerance,” Journal of Experimental Medicine 216, no. 1 (2019): 99-116.

[40] J. Han, H. Son, D. Jung, et al., “Comparison of Natural Killer Cells Differentiated From Various Pluripotent Stem Cells,” International Journal of Molecular Sciences 25, no. 15 (2024): 8209.

[41] Q. Zhang, C. Xia, Q. Weng, et al., “Hypoimmunogenic CD19 CAR-NK Cells Derived From Embryonic Stem Cells Suppress the Progression of Human B-Cell Malignancies in Xenograft Animals,” Frontiers in Immunology 15 (2024): 1504459, https://doi.org/10.3389/fimmu.2024.1504459.

[42] Q. Hammer, K. Perica, R. M. Mbofung, et al., “Genetic Ablation of Adhesion Ligands Mitigates Rejection of Allogeneic Cellular Immunotherapies,” Cell Stem Cell 31, no. 9 (2024): 1376-1386.e8.

[43] G. Maki, H. G. Klingemann, J. A. Martinson, and Y. K. Tam, “Factors Regulating the Cytotoxic Activity of the Human Natural Killer Cell Line, NK-92,” Journal of Hematotherapy and Stem Cell Research 10, no. 3 (2001): 369-383.

[44] N. Kim, E. Yi, E. Lee, H. J. Park, and H. S. Kim, “Interleukin-2 Is Required for NKp30-Dependent NK Cell Cytotoxicity by Preferentially Regulating NKp30 Expression,” Frontiers in Immunology 15 (2024): 1388018.

[45] K. Brocke-Heidrich, A. K. Kretzschmar, G. Pfeifer, et al., “Interleukin-6-Dependent Gene Expression Profiles in Multiple Myeloma INA-6 Cells Reveal a Bcl-2 Family-Independent Survival Pathway Closely Associated With Stat3 Activation,” Blood 103, no. 1 (2004): 242-251.

[46] B. Zheng, Y. Yang, Q. Han, C. Yin, Z. Pan, and J. Zhang, “STAT3 Directly Regulates NKp46 Transcription in NK Cells of HBeAg-Negative CHB Patients,” Journal of Leukocyte Biology 106, no. 4 (2019): 987-996.

[47] A. Witalisz-Siepracka, K. Klein, B. Zdársky, et al., “The Multifaceted Role of STAT3 in NK-Cell Tumor Surveillance,” Frontiers in Immunology 13 (2022): 947568.

[48] R. Teng, Y. Wang, N. Lv, et al., “Hypoxia Impairs NK Cell Cytotoxicity Through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways,” Journal of Immunology Research 2020 (2020): 4598476.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.